NASDAQ:NERV

Minerva Neurosciences Stock Forecast, Price & News

$3.19

-0.11 (-3.33 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.18

Now: $3.19▼

$3.39

50-Day Range

$2.26

MA: $2.60▼

$3.45

52-Week Range

$1.81

Now: $3.19▼

$15.22

Volume758,358 shs

Average Volume1.37 million shs

Market Capitalization$136.13 million

P/E RatioN/A

Dividend YieldN/A

Beta1.49

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.55 out of 5 stars

Medical Sector

358th out of 1,926 stocks

Pharmaceutical Preparations Industry

188th out of 773 stocks

3.3 Analyst's Opinion

Consensus Rating
Minerva Neurosciences has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.75, Minerva Neurosciences has a forecasted upside of 111.6% from its current price of $3.19.
Amount of Analyst Coverage
Minerva Neurosciences has received no research coverage in the past 90 days.

2.8 Community Rank

Outperform Votes
Minerva Neurosciences has received 337 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Minerva Neurosciences has received 269 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Minerva Neurosciences has received 55.61% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote “Outperform” if you believe NERV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Minerva Neurosciences does not currently pay a dividend.
Dividend Growth
Minerva Neurosciences does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Minerva Neurosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,166.00 in company stock.
Percentage Held by Insiders
Only 12.00% of the stock of Minerva Neurosciences is held by insiders.
Percentage Held by Institutions
66.28% of the stock of Minerva Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Minerva Neurosciences are expected to decrease in the coming year, from $0.02 to ($0.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Minerva Neurosciences is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Minerva Neurosciences is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Minerva Neurosciences has a P/B Ratio of 4.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NERV

Previous Symbol

CUSIPN/A

CIK1598646

Webwww.minervaneurosciences.com

Phone617-600-7373

Employees13

Debt

Debt-to-Equity RatioN/A

Current Ratio6.49

Quick Ratio6.49

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio159.50

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.71 per share

Price / Book4.49

Profitability

EPS (Most Recent Fiscal Year)($1.85)

Net Income$-72,180,000.00

Net MarginsN/A

Return on Equity-51.19%

Return on Assets-29.75%

Miscellaneous

Outstanding Shares42,674,000

Market Cap$136.13 million

Next Earnings Date3/8/2021 (Estimated)

OptionableOptionable

$3.19

-0.11 (-3.33 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

How has Minerva Neurosciences' stock been impacted by Coronavirus (COVID-19)?

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NERV shares have decreased by 49.8% and is now trading at $3.19.
View which stocks have been most impacted by COVID-19.

Is Minerva Neurosciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Minerva Neurosciences stock.
View analyst ratings for Minerva Neurosciences or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Minerva Neurosciences?

Wall Street analysts have given Minerva Neurosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Minerva Neurosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Minerva Neurosciences' CEO?

1,448 employees have rated Minerva Neurosciences CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Minerva Neurosciences' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Minerva Neurosciences.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) released its quarterly earnings data on Monday, November, 2nd. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03.
View Minerva Neurosciences' earnings history.

What price target have analysts set for NERV?

5 equities research analysts have issued 12-month price objectives for Minerva Neurosciences' shares. Their forecasts range from $2.00 to $10.00. On average, they expect Minerva Neurosciences' stock price to reach $6.75 in the next year. This suggests a possible upside of 111.6% from the stock's current price.
View analysts' price targets for Minerva Neurosciences or view Wall Street analyst' top-rated stocks.

Who are some of Minerva Neurosciences' key competitors?

Some companies that are related to Minerva Neurosciences include Prothena (PRTA), Pandion Therapeutics (PAND), resTORbio (TORC), Five Prime Therapeutics (FPRX), Geron (GERN), Urovant Sciences (UROV), IDEAYA Biosciences (IDYA), RAPT Therapeutics (RAPT), Cogent Biosciences (UMRX), Forte Biosciences (FBRX), XBiotech (XBIT), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), BioVie (BIVI) and Spruce Biosciences (SPRB).
View all of NERV's competitors.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:

Mr. Geoffrey Robin Race, Exec. VP, CFO & Chief Bus. Officer (Age 60, Pay $516.84k)
Mr. Joseph Reilly, Sr. VP & COO (Age 46)
Mr. Frederick W. Ahlholm, Sr. VP & Chief Accounting Officer (Age 55)
Mr. William B. Boni, VP of Investor Relations & Corp. Communications (Age 69)
Mr. Devin Whittemore Smith, Sr. VP, Gen. Counsel & Sec. (Age 53)
Dr. Michael Davidson, Chief Medical Officer (Age 71)
Dr. Jay B. Saoud Ph.D., Sr. VP and Head of R&D (Age 62)

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $3.19.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $136.13 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here